ScientificMed is teaming up with Microsoft

ScientificMed has been selected to the Microsoft for Statups Europe program. The program and partnership will accelerate the development and implementation of the company's next generation oncology Digital Therapeutics and Patient Engagement Platform.

The platform is build on Azure and the FHIR standard for improved interoperability, AI/machine learning, and scalability.

For further information, please contact Jan Fjellström, ScientificMed, +46 708 63 60 00.

Funding granted for a clinical trial on the effects of a DTx in breast cancer treatment

ScientificMed, together with researchers and clinicians from three hospitals in Stockholm, has been granted funding from the Swedish Breast Cancer Association (Bröstcancerförbundet) for a clinical trial (RCT) targeting women with endocrine adjuvant therapy breast cancer.

The purpose of the RCT is to study whether using a Digital Therapeutic (DTx) as support increase adherence to adjuvant endocrine therapy, reduce the late effects of treatment and increase quality of life. The secondary aims are to study health economic effects, compliance to usage of the app and its perceived usability.

For further information, please contact Jan Fjellström, ScientificMed, +46 708 63 60 00.

DTx to support prostate cancer patients undergoing antihormone therapy

ScientificMed in collaboration with leading Nordic hospitals and a pharmaceutical company has developed a patient app (Digital Therapeutics, DTx) to support prostate cancer patients undergoing antihormone therapy. The app supports the patients with a targeted exercise program in order to counteract side effects of the therapy.

For further information, please contact Jan Fjellström, ScientificMed, +46 708 63 60 00